Reuters logo
5 months ago
BRIEF-Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions
March 7, 2017 / 2:37 PM / 5 months ago

BRIEF-Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions

1 Min Read

March 7 (Reuters) - Regeneron Pharmaceuticals Inc

* Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions

* Regeneron Pharmaceuticals Inc says effect of praluent on cardiovascular (CV) morbidity and mortality has not yet been determined Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below